Frontiers in pharmacology · 2026
CircHIPK3 promotes the progression of B-cell acute lymphoblastic leukemia in children by binding to STAT3.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Yu, Li Yunpeng, Zhu Xiuli, Chen Yan, Diao Yuqiao
Аннотация
BACKGROUND: Circular RNAs (circRNAs) have emerged as critical post-transcriptional regulators in hematological malignancies; however, the specific role and molecular mechanism of circHIPK3 in pediatric B-cell acute lymphoblastic leukemia (B-ALL) remain unexplored.
METHODS: circHIPK3 expression was profiled in clinical B-ALL specimens and cell lines. The biological functions were evaluated using CCK-8, flow cytometry, and in vivo NOD/SCID xenograft models for leukemic infiltration assessment. Mechanistic interactions were deciphered via RNA immunoprecipitation (RIP), RNA pull-down, and ubiquitination assays.
RESULTS: CircHIPK3 was aberrantly upregulated in B-ALL tissues and cells, exhibiting exceptional stability and predominant cytoplasmic localization. CircHIPK3 silencing significantly impaired leukemic cell proliferation, induced G0/G1 cell cycle arrest, and triggered apoptosis. Mechanistically, we identified a direct physical association between cytoplasmic circHIPK3 and STAT3. CircHIPK3 did not alter STAT3 transcription but rather acted as a protein scaffold that shielded STAT3 from ubiquitin-mediated proteasomal degradation, thereby enhancing its protein stability. Ectopic STAT3 expression reversed the tumor-suppressive phenotypes caused by circHIPK3 deficiency. Consistently, circHIPK3 knockdown attenuated leukemic infiltration in xenograft mice.
CONCLUSION: Our findings characterize circHIPK3 as a potent oncogenic driver in B-ALL that functions by stabilizing STAT3 via the ubiquitin-proteasome pathway. Targeting the circHIPK3/STAT3 axis may represent a potential therapeutic strategy for B-ALL treatment.
METHODS: circHIPK3 expression was profiled in clinical B-ALL specimens and cell lines. The biological functions were evaluated using CCK-8, flow cytometry, and in vivo NOD/SCID xenograft models for leukemic infiltration assessment. Mechanistic interactions were deciphered via RNA immunoprecipitation (RIP), RNA pull-down, and ubiquitination assays.
RESULTS: CircHIPK3 was aberrantly upregulated in B-ALL tissues and cells, exhibiting exceptional stability and predominant cytoplasmic localization. CircHIPK3 silencing significantly impaired leukemic cell proliferation, induced G0/G1 cell cycle arrest, and triggered apoptosis. Mechanistically, we identified a direct physical association between cytoplasmic circHIPK3 and STAT3. CircHIPK3 did not alter STAT3 transcription but rather acted as a protein scaffold that shielded STAT3 from ubiquitin-mediated proteasomal degradation, thereby enhancing its protein stability. Ectopic STAT3 expression reversed the tumor-suppressive phenotypes caused by circHIPK3 deficiency. Consistently, circHIPK3 knockdown attenuated leukemic infiltration in xenograft mice.
CONCLUSION: Our findings characterize circHIPK3 as a potent oncogenic driver in B-ALL that functions by stabilizing STAT3 via the ubiquitin-proteasome pathway. Targeting the circHIPK3/STAT3 axis may represent a potential therapeutic strategy for B-ALL treatment.